These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10337934)

  • 21. [The clinical characteristics of primary biliary cirrhosis in China: a systematic review].
    Gu EL; Yao GB
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):861-6. PubMed ID: 19958649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical correlation of antimitochondrial antibodies.
    Zuber MA; Recktenwald C
    Eur J Med Res; 2003 Feb; 8(2):61-70. PubMed ID: 12626283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary biliary cirrhosis and hepatitis C virus infection.
    Floreani A; Baragiotta A; Leone MG; Baldo V; Naccarato R
    Am J Gastroenterol; 2003 Dec; 98(12):2757-62. PubMed ID: 14687829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The value of antimitochondrial antibody and its subtypes in the diagnosis of primary biliary cirrhosis].
    Yao DK; Xie WF; Chen WZ; Liu HY; Tu XQ; Fan LY
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jan; 13(1):9-11. PubMed ID: 15670482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical characteristics of primary biliary cirrhosis: a report of 45 cases].
    Zhang F; Jia J; Wang B; Qian L; Yin S; Wang Y; Cui Y; You H; Ma H; Wang H; Zhang C
    Zhonghua Nei Ke Za Zhi; 2002 Mar; 41(3):163-7. PubMed ID: 11940315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis.
    Oertelt S; Rieger R; Selmi C; Invernizzi P; Ansari AA; Coppel RL; Podda M; Leung PS; Gershwin ME
    Hepatology; 2007 Mar; 45(3):659-65. PubMed ID: 17326160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High levels of soluble CTLA-4 are present in anti-mitochondrial antibody positive, but not in antibody negative patients with primary biliary cirrhosis.
    Saverino D; Pesce G; Antola P; Porcelli B; Brusca I; Villalta D; Tampoia M; Tozzoli R; Tonutti E; Alessio MG; Bagnasco M; Bizzaro N
    PLoS One; 2014; 9(11):e112509. PubMed ID: 25383768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated level of serum Mn-superoxide dismutase in patients with primary biliary cirrhosis: possible involvement of free radicals in the pathogenesis in primary biliary cirrhosis.
    Ono M; Sekiya C; Ohhira M; Ohhira M; Namiki M; Endo Y; Suzuki K; Matsuda Y; Taniguchi N
    J Lab Clin Med; 1991 Nov; 118(5):476-83. PubMed ID: 1682406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serological comparative proteomics analysis of mitochondrial autoantibody-negative and -positive primary biliary cirrhosis.
    Deng C; Hu C; Wang L; Zhang S; Li P; Wu Z; Chen S; Zhang F; Li Y
    Electrophoresis; 2015 Jul; 36(14):1588-95. PubMed ID: 25875855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis.
    Juliusson G; Imam M; Björnsson ES; Talwalkar JA; Lindor KD
    Scand J Gastroenterol; 2016; 51(6):745-52. PubMed ID: 26776319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The significance of antimitochondrial IgA and IgG in the diagnosis of primary biliary cirrhosis].
    Lu JX; Qian SY; Shu X; Li G
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):905-9. PubMed ID: 20038331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis.
    Rigopoulou EI; Davies ET; Bogdanos DP; Liaskos C; Mytilinaiou M; Koukoulis GK; Dalekos GN; Vergani D
    Liver Int; 2007 Nov; 27(9):1226-31. PubMed ID: 17919234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis.
    Invernizzi P; Crosignani A; Battezzati PM; Covini G; De Valle G; Larghi A; Zuin M; Podda M
    Hepatology; 1997 May; 25(5):1090-5. PubMed ID: 9141422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case of primary biliary cirrhosis accompanied with fibrinogen storage disease.
    Mitsui H; Miyauchi E; Miyahara J; Wada K; Yamakawa M; Kawata S
    Pathol Res Pract; 2005; 201(4):341-5. PubMed ID: 15991842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactivity of anti-mitochondrial autoantibodies in primary biliary cirrhosis: definition of two novel mitochondrial polypeptide autoantigens.
    Frazer IH; Mackay IR; Jordan TW; Whittingham S; Marzuki S
    J Immunol; 1985 Sep; 135(3):1739-45. PubMed ID: 2410503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis.
    Agmon-Levin N; Shapira Y; Selmi C; Barzilai O; Ram M; Szyper-Kravitz M; Sella S; Katz BS; Youinou P; Renaudineau Y; Larida B; Invernizzi P; Gershwin ME; Shoenfeld Y
    J Autoimmun; 2010 Feb; 34(1):55-8. PubMed ID: 19897339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti-mitochondrial antibodies but without baseline PBC.
    Duan W; Chen S; Li S; Lv T; Li B; Wang X; Wang Y; Zhao X; Ma H; Ou X; You H; Jia J
    Hepatol Commun; 2022 Nov; 6(11):3112-3119. PubMed ID: 35998274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimitochondrial antibody-negative primary biliary cirrhosis.
    Mendes F; Lindor KD
    Gastroenterol Clin North Am; 2008 Jun; 37(2):479-84, viii. PubMed ID: 18499032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Negative conversion of antimitochondrial antibody in primary biliary cirrhosis: a case of autoimmune cholangitis.
    Cho YJ; Han DS; Kim TY; Jang SJ; Jeon YC; Sohn JH; Lee IH; Park KN
    J Korean Med Sci; 1999 Feb; 14(1):102-6. PubMed ID: 10102534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.